DIEPENBEEK, Belgium--(BUSINESS WIRE)--Amakem announces today that it has been awarded 1.28M€ by the Flemish government agency for Innovation by Science and Technology (IWT) to support its Rho kinase (ROCK) inhibitor-based drug development program for chronic obstructive pulmonary disease (COPD).
